Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 Study

This publication was sponsored by Debiopharm International SA.

This Clinical Brief explores the double-blind, multicentre, randomised phase 2 study (NCT02022098) of Debio 1143 and high-dose cisplatin chemoradiotherapy in patients with high-risk locoregionally advanced squamous cell carcinoma of the head and neck.

Download PDF